BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lonardo A. Renaming NAFLD to MAFLD: Could the LDE System Assist in This Transition? J Clin Med 2021;10:492. [PMID: 33572544 DOI: 10.3390/jcm10030492] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Lonardo A. Back to the future: From the history of NAFLD to MAFLD to heterogeneity of disease. Clinical and Translational Dis 2021;1. [DOI: 10.1002/ctd2.9] [Reference Citation Analysis]
2 Lonardo A. Metabolomic signature: one step forward in the process of obtaining NAFLD patients' metabolic identity card. Am J Clin Nutr 2022;115:603-5. [PMID: 35134121 DOI: 10.1093/ajcn/nqab399] [Reference Citation Analysis]
3 Lonardo A. Separating the apples from the oranges: from NAFLD heterogeneity to personalized medicine. Exploration of Medicine. [DOI: 10.37349/emed.2021.00061] [Reference Citation Analysis]
4 Barrios V, López-Villar E, Frago LM, Canelles S, Díaz-González F, Burgos-Ramos E, Frühbeck G, Chowen JA, Argente J. Cerebral Insulin Bolus Revokes the Changes in Hepatic Lipid Metabolism Induced by Chronic Central Leptin Infusion. Cells 2021;10:581. [PMID: 33800837 DOI: 10.3390/cells10030581] [Reference Citation Analysis]
5 Lonardo A. Separating the apples from the oranges: from NAFLD heterogeneity to personalized medicine. Exploration of Medicine. [DOI: 10.37349/emed.2021.00061] [Reference Citation Analysis]
6 Seo JY, Bae JH, Kwak MS, Yang JI, Chung SJ, Yim JY, Lim SH, Chung GE. The Risk of Colorectal Adenoma in Nonalcoholic or Metabolic-Associated Fatty Liver Disease. Biomedicines 2021;9:1401. [PMID: 34680518 DOI: 10.3390/biomedicines9101401] [Reference Citation Analysis]
7 Xue R, Su L, Lai S, Wang Y, Zhao D, Fan J, Chen W, Hylemon PB, Zhou H. Bile Acid Receptors and the Gut-Liver Axis in Nonalcoholic Fatty Liver Disease. Cells 2021;10:2806. [PMID: 34831031 DOI: 10.3390/cells10112806] [Reference Citation Analysis]
8 Lim S, Kim JW, Targher G. Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease. Trends Endocrinol Metab 2021;32:500-14. [PMID: 33975804 DOI: 10.1016/j.tem.2021.04.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
9 Milic J, Barbieri S, Gozzi L, Brigo A, Beghé B, Verduri A, Bacca E, Iadisernia V, Cuomo G, Dolci G, Yaacoub D, Aprile E, Belli M, Venuta M, Meschiari M, Sebastiani G, Clini E, Mussini C, Lonardo A, Guaraldi G, Raggi P. Metabolic-Associated Fatty Liver Disease Is Highly Prevalent in the Postacute COVID Syndrome. Open Forum Infect Dis 2022;9:ofac003. [PMID: 35146047 DOI: 10.1093/ofid/ofac003] [Reference Citation Analysis]